| scholarly article | Q13442814 |
| P356 | DOI | 10.1038/S41598-020-75118-1 |
| P698 | PubMed publication ID | 33093566 |
| P2093 | author name string | Miguel E Quiñones-Mateu | |
| John C Tilton | |||
| Aiman A Haqqani | |||
| Caroline O Tabler | |||
| Jake A Galiatsos | |||
| Lauren E Lapointe | |||
| Michał M Bonar | |||
| Samira Joussef-Piña | |||
| P2860 | cites work | Terminal Interface Conformations Modulate Dimer Stability Prior to Amino Terminal Autoprocessing of HIV-1 Protease | Q27676717 |
| A Simple Statistical Parameter for Use in Evaluation and Validation of High Throughput Screening Assays | Q28145712 | ||
| Contribution of human immunodeficiency virus type 1 minority variants to reduced drug susceptibility in patients on an integrase strand transfer inhibitor-based therapy | Q28541754 | ||
| Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection | Q29619510 | ||
| Inhibition of autoprocessing of natural variants and multidrug resistant mutant precursors of HIV-1 protease by clinical inhibitors | Q35022049 | ||
| Sorting of small infectious virus particles by flow virometry reveals distinct infectivity profiles. | Q35043212 | ||
| ??? | Q57904706 | ||
| High sensitivity detection and sorting of infectious human immunodeficiency virus (HIV-1) particles by flow virometry | Q36290494 | ||
| Partial inhibition of the human immunodeficiency virus type 1 protease results in aberrant virus assembly and the formation of noninfectious particles. | Q36650046 | ||
| Incorporation of Vpr into human immunodeficiency virus type 1 virions: requirement for the p6 region of gag and mutational analysis. | Q36655127 | ||
| Nanoparticle-based flow virometry for the analysis of individual virions | Q37123872 | ||
| Prototypical Recombinant Multi-Protease-Inhibitor-Resistant Infectious Molecular Clones of Human Immunodeficiency Virus Type 1 | Q37124113 | ||
| Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2016 Recommendations of the International Antiviral Society-USA Panel | Q37234729 | ||
| Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection | Q37273158 | ||
| Noninvasive high-throughput single-cell analysis of HIV protease activity using ratiometric flow cytometry | Q37482762 | ||
| Visualization of human immunodeficiency virus protease inhibition using a novel Förster resonance energy transfer molecular probe | Q38267082 | ||
| Novel single-cell-level phenotypic assay for residual drug susceptibility and reduced replication capacity of drug-resistant human immunodeficiency virus type 1. | Q38449098 | ||
| Recent Progress in the Development of HIV-1 Protease Inhibitors for the Treatment of HIV/AIDS | Q38708006 | ||
| Quantitative Evaluation of Protein Heterogeneity within Herpes Simplex Virus 1 Particles. | Q38919636 | ||
| Nipah virion entry kinetics, composition, and conformational changes determined by enzymatic virus-like particles and new flow virometry tools | Q38951339 | ||
| Flexible catalytic site conformations implicated in modulation of HIV-1 protease autoprocessing reactions | Q38972969 | ||
| Cell-based fluorescence assay for human immunodeficiency virus type 1 protease activity | Q39478324 | ||
| Importance of protease cleavage sites within and flanking human immunodeficiency virus type 1 transframe protein p6* for spatiotemporal regulation of protease activation. | Q40005589 | ||
| Use of a novel assay based on intact recombinant viruses expressing green (EGFP) or red (DsRed2) fluorescent proteins to examine the contribution of pol and env genes to overall HIV-1 replicative fitness | Q40281163 | ||
| T-cell line for HIV drug screening using EGFP as a quantitative marker of HIV-1 replication | Q40321706 | ||
| Bis-anthracycline antibiotics inhibit human immunodeficiency virus type 1 transcription | Q40563544 | ||
| Initial cleavage of the human immunodeficiency virus type 1 GagPol precursor by its activated protease occurs by an intramolecular mechanism | Q41275889 | ||
| Ordered processing of the human immunodeficiency virus type 1 GagPol precursor is influenced by the context of the embedded viral protease | Q41997191 | ||
| Novel method for simultaneous quantification of phenotypic resistance to maturation, protease, reverse transcriptase, and integrase HIV inhibitors based on 3'Gag(p2/p7/p1/p6)/PR/RT/INT-recombinant viruses: a useful tool in the multitarget era of ant | Q42148219 | ||
| Quantitative assessment of in vivo HIV protease activity using genetically engineered QD-based FRET probes | Q42240414 | ||
| Western blots versus selected reaction monitoring assays: time to turn the tables? | Q42595907 | ||
| CD4+ T cell kinetics and activation in human immunodeficiency virus-infected patients who remain viremic despite long-term treatment with protease inhibitor-based therapy | Q43864378 | ||
| Single-Particle Discrimination of Retroviruses from Extracellular Vesicles by Nanoscale Flow Cytometry. | Q47126636 | ||
| Misleading Westerns: Common Quantification Mistakes in Western Blot Densitometry and Proposed Corrective Measures | Q64230716 | ||
| P433 | issue | 1 | |
| P921 | main subject | flow cytometry | Q1141429 |
| infectivity | Q1662346 | ||
| P304 | page(s) | 18101 | |
| P577 | publication date | 2020-10-22 | |
| P1433 | published in | Scientific Reports | Q2261792 |
| P1476 | title | Nanoscale flow cytometry reveals interpatient variability in HIV protease activity that correlates with viral infectivity and identifies drug-resistant viruses | |
| P478 | volume | 10 |
Search more.